Big data to smart data in Alzheimer's disease: The brain health modeling initiative to foster actionable knowledge

Alzheimer's and Dementia

Volumn 12, Issue 9, 2016, Pages 1014-1021

  Geerts, Hugo ^a   Dacks, Penny A ^b   Devanarayan, Viswanath ^c   Haas, Magali ^d   Khachaturian, Zaven S ^e   Gordon, Mark Forrest ^f   Maudsley, Stuart ^g   Romero, Klaus ^h   Stephenson, Diane ^h  

^a In Silico Biosciences   (United States)

^b Alzheimers Drug Discovery Foundation   (United States)

^c Abbvie   (United States)

^d Orion Bionetworks   (United States)

^e PAD2020   (United States)

^f BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^g UNIVERSITY OF ANTWERP   (Belgium)

^h CRITICAL PATH INSTITUTE   (United States)

Author keywords

Alzheimer's dementia; Brain disorders; Complexity theory; Drug discovery and development; Systems biology; Systems pharmacology

Indexed keywords

ALZHEIMER DISEASE; COMPUTER MODEL; COMPUTER SIMULATION; CONCEPTUAL FRAMEWORK; DATA PROCESSING; DRUG DEVELOPMENT; HUMAN; MATHEMATICAL MODEL; MEDICAL INFORMATION; MENTAL HEALTH; NEUROSCIENCE; PHARMACOLOGY; PRIORITY JOURNAL; REVIEW; SYSTEMS BIOLOGY; ANIMAL; BIOLOGICAL MODEL; BRAIN; DRUG EFFECTS; FACTUAL DATABASE; PATHOPHYSIOLOGY; PROCEDURES;

ALZHEIMER DISEASE; ANIMALS; BRAIN; COMPUTER SIMULATION; DATABASES, FACTUAL; DRUG DISCOVERY; HUMANS; MODELS, NEUROLOGICAL;

EID: 84977647614     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2016.04.008     Document Type: Review

References (44)

1. [1] Gustavsson, A., Svensson, M., Jacobi, F., Allgulander, C., Alonso, J., Beghi, E., et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21 (2011), 718–779.
2. [2] Hurd, M.D., Martorell, P., Delavande, A., Mullen, K.J., Langa, K.M., Monetary costs of dementia in the United States. N Engl J Med 368 (2013), 1326–1334.
3. [3] Plassman, B.L., Langa, K.M., Fisher, G.G., Heeringa, S.G., Weir, D.R., Ofstedal, M.B., et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 29 (2007), 125–132.
4. [4] Cummings, J.L., Morstorf, T., Zhong, K., Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther, 6, 2014, 37.
5. [5] Zahs, K.R., Ashe, K.H., ‘Too much good news’ - are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease?. Trends Neurosci 33 (2010), 381–389.
6. [6] Shineman, D.W., Basi, G.S., Bizon, J.L., Colton, C.A., Greenberg, B.D., Hollister, B.A., et al. Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies. Alzheimers Res Ther, 3, 2011, 28.
7. [7] Geerts, H., Of mice and men: bridging the translational disconnect in CNS drug discovery. CNS Drugs 23 (2009), 915–926.
8. [8] Schneider, J.A., Arvanitakis, Z., Leurgans, S.E., Bennett, D.A., The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 66 (2009), 200–208.
9. [9] Bennett, D.A., Schneider, J.A., Arvanitakis, Z., Kelly, J.F., Aggarwal, N.T., Shah, R.C., et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 66 (2006), 1837–1844.
10. [10] Romero, K., Ito, K., Rogers, J.A., Polhamus, D., Qiu, R., Stephenson, D., et al. The future is now: model-based clinical trial design for Alzheimer's disease. Clin Pharmacol Ther 97 (2015), 210–214.
11. [11] Panza, F., Solfrizzi, V., Imbimbo, B.P., Tortelli, R., Santamato, A., Logroscino, G., Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. Expert Rev Clin Immunol 10 (2014), 405–419.
12. [12] Garai, K., Frieden, C., Quantitative analysis of the time course of Abeta oligomerization and subsequent growth steps using tetramethylrhodamine-labeled Abeta. Proc Natl Acad Sci U S A 110 (2013), 3321–3326.
13. [13] Potter, R., Patterson, B.W., Elbert, D.L., Ovod, V., Kasten, T., Sigurdson, W., et al. Increased in vivo amyloid-beta42 production, exchange, and loss in presenilin mutation carriers. Sci Transl Med, 5, 2013, 189ra77.
14. [14] Wang, Y., Zhou, T.H., Zhi, Z., Barakat, A., Hlatky, L., Querfurth, H., Multiple effects of beta-amyloid on single excitatory synaptic connections in the PFC. Front Cell Neurosci, 7, 2013, 129.
15. [15] Geerts, H., Spiros, A., Roberts, P., Assessing the synergy between cholinomimetics and memantine as augmentation therapy in cognitive impairment in schizophrenia. A virtual human patient trial using quantitative systems pharmacology. Front Pharmacol, 6, 2015, 198.
16. [16] Smith, N., Noble, D., Knowledge capture and the responsibility: past and present. Prog Biophys Mol Biol 96 (2008), 1–2.
17. [17] Roberts, P.D., Spiros, A., Geerts, H., Simulations of symptomatic treatments for Alzheimer's disease: computational analysis of pathology and mechanisms of drug action. Alzheimers Res Ther, 4, 2012, 50.
18. [18] Husain, M., Big data: could it ever cure Alzheimer's disease?. Brain 137 (2014), 2623–2624.
19. [19] Saykin, A.J., Shen, L., Yao, X., Kim, S., Nho, K., Risacher, S.L., et al. Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans. Alzheimers Dement 11 (2015), 792–814.
20. [20] Choi, I.Y., Kim, T.M., Kim, M.S., Mun, S.K., Chung, Y.J., Perspectives on clinical informatics: integrating large-scale clinical, genomic, and health information for clinical care. Genomics Inform 11 (2013), 186–190.
21. [21] Bai, J.P., Abernethy, D.R., Systems pharmacology to predict drug toxicity: integration across levels of biological organization. Annu Rev Pharmacol Toxicol 53 (2013), 451–473.
22. [22] Maudsley, S., Martin, B., Janssens, J., Etienne, H., Jushaj, A., van Gastel, J., et al. Informatic deconvolution of biased GPCR signaling mechanisms from in vivo pharmacological experimentation. Methods 92 (2016), 51–63.
23. [23] Schmitt, W., Willmann, S., Physiology-based pharmacokinetic modeling: ready to be used. Drug Discov Today Technol 1 (2004), 449–456.
24. [24] Sinha, V., Zhao, P., Huang, S.M., Zineh, I., Physiologically based pharmacokinetic modeling: from regulatory science to regulatory policy. Clin Pharmacol Ther 95 (2014), 478–480.
25. [25] Peterson, M.C., Riggs, M.M., FDA Advisory meeting clinical pharmacology review utilizes a quantitative systems pharmacology (QSP) model: a watershed moment?. CPT Pharmacometrics Syst Pharmacol, 4, 2015, e00020.
26. [26] Bhattacharya, S., Shoda, L.K., Zhang, Q., Woods, C.G., Howell, B.A., Siler, S.Q., et al. Modeling drug- and chemical-induced hepatotoxicity with systems biology approaches. Front Physiol, 3, 2012, 462.
27. [27] Nicholas, T., Duvvuri, S., Leurent, C., Raunig, D., Rapp, T., Iredale, R., et al. Systems pharmacology modeling in neuroscience: prediction and outcome of PF-04995274, a 5HT4 partial agonist, in a clinical scopolamine impairment trial. Adv Alzheimers Dis 2 (2013), 83–98.
28. [28] Lapish, C.C., Balaguer-Ballester, E., Seamans, J.K., Phillips, A.G., Durstewitz, D., Amphetamine exerts dose-dependent changes in prefrontal cortex attractor dynamics during working memory. J Neurosci 35 (2015), 10172–10187.
29. [29] Durstewitz, D., Seamans, J., Beyond bistability: Biophysics and temporal dynamics of working memory. Neuroscience 139 (2006), 119–133.
30. [30] Chou, H.H., Talledo, J.A., Lamb, S.N., Thompson, W.K., Swerdlow, N.R., Amphetamine effects on MATRICS Consensus Cognitive Battery performance in healthy adults. Psychopharmacology (Berl) 227 (2013), 165–176.
31. [31] Little, S., Pogosyan, A., Neal, S., Zavala, B., Zrinzo, L., Hariz, M., et al. Adaptive deep brain stimulation in advanced Parkinson disease. Ann Neurol 74 (2013), 449–457.
32. [32] Zueva, M.V., Fractality of sensations and the brain health: the theory linking neurodegenerative disorder with distortion of spatial and temporal scale-invariance and fractal complexity of the visible world. Front Aging Neurosci, 7, 2015, 135.
33. [33] Lehnertz, K., Non-linear time series analysis of intracranial EEG recordings in patients with epilepsy–an overview. Int J Psychophysiol 34 (1999), 45–52.
34. [34] Korn, H., Faure, P., Is there chaos in the brain? II. Experimental evidence and related models. C R Biol 326 (2003), 787–840.
35. [35] Plenz, D., Thiagarajan, T.C., The organizing principles of neuronal avalanches: cell assemblies in the cortex?. Trends Neurosci 30 (2007), 101–110.
36. [36] Grigolini, P., Piccinini, N., Svenkeson, A., Pramukkul, P., Lambert, D., West, B.J., From neural and social cooperation to the global emergence of cognition. Front Bioeng Biotechnol, 3, 2015, 78.
37. [37] Quinn, J.F., Raman, R., Thomas, R.G., Yurko-Mauro, K., Nelson, E.B., Van Dyck, C., et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA 304 (2010), 1903–1911.
38. [38] Huang, T.L., Omega-3 fatty acids, cognitive decline, and Alzheimer's disease: a critical review and evaluation of the literature. J Alzheimers Dis 21 (2010), 673–690.
39. [39] Vandal, M., Alata, W., Tremblay, C., Rioux-Perreault, C., Salem, N. Jr., Calon, F., et al. Reduction in DHA transport to the brain of mice expressing human APOE4 compared to APOE2. J Neurochem 129 (2014), 516–526.
40. [40] Hennebelle, M., Plourde, M., Chouinard-Watkins, R., Castellano, C.A., Barberger-Gateau, P., Cunnane, S.C., Ageing and apoE change DHA homeostasis: relevance to age-related cognitive decline. Proc Nutr Soc 73 (2014), 80–86.
41. [41] Samieri, C., Lorrain, S., Buaud, B., Vaysse, C., Berr, C., Peuchant, E., et al. Relationship between diet and plasma long-chain n-3 PUFAs in older people: impact of apolipoprotein E genotype. J Lipid Res 54 (2013), 2559–2567.
42. [42] Collins, F.S., Varmus, H., A new initiative on precision medicine. N Engl J Med 372 (2015), 793–795.
43. [43] Yuraszeck, T.M., Neveu, P., Rodriguez-Fernandez, M., Robinson, A., Kosik, K.S., Doyle, F.J. 3rd, Vulnerabilities in the tau network and the role of ultrasensitive points in tau pathophysiology. PLoS Comput Biol, 6, 2010, e1000997.
44. [44] Zak, D.E., Gonye, G.E., Schwaber, J.S., Doyle, F.J. 3rd, Importance of input perturbations and stochastic gene expression in the reverse engineering of genetic regulatory networks: insights from an identifiability analysis of an in silico network. Genome Res 13 (2003), 2396–2405.